Q1: 2026-05-05 Earnings Summary EPS of -$1.54 misses by $0.08  |  Revenue of $136.00M (-2.36% Y/Y) misses by $22.41M Ultragenyx Pharmaceutical Inc. ( RARE ) Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDT Company Participants Howard Horn - Executive VP of Corporate Strategy & CFO Joshua Higa - Director of Investor Relations & Corporate Communications Presentation Unknown Analyst I'm one of the biotech analysts here at BofA. Our next presenting company is Ultragenyx. And here with me are Howard Horn, Chief Financial Officer; and Josh Higa, Head of IR. Thank you for joining us, guys. Question-and-Answer Session Unknown Analyst So I think there's a lot going on at the company. I think most people are familiar with it, but maybe we can start with a quick overview of the company, kind of your commercial products, and you have a very busy second half of the year. So maybe you can highlight some of the key catalysts coming up.…